Abstract
Cytomegalovirus results in significant morbidity and mortality following lung transplantation. Ganciclovir prophylaxis has significantly reduced CMV-related complications, however ganciclovir resistance and the resultant morbidity and mortality is still identified in 5-10% of CMV-infected patients. Malabsorption of valganciclovir or increased elimination of ganciclovir may lead to subtherapeutic levels and ganciclovir resistance. Diseases in which malabsorption or rapid elimination occurs, such as cystic fibrosis, may be at increased risk for ganciclovir resistance.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
